Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | KAT7 | O95251 | 1/20 | 0.36 |
| ▸ | YAP1 | P46937 | 3/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.35 |
| ▸ | MMP13 | P45452 | 3/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493707 | 0.91 | CA1 (0.35) | ABHD6DAGLA | |
| SCHEMBL3494719 | 0.91 | ABHD6 (0.44) | ABHD6DAGLANR1H2NR1H3DPP4 | |
| SCHEMBL8235365 | 0.88 | NR1H2 (0.44) | ABHD6DAGLAGPR119NR1H2NR1H3 | |
| SCHEMBL8238421 | 0.87 | KAT7 (0.39) | ABHD6DAGLAGPR119NR1H2NR1H3 | |
| SCHEMBL8238325 | 0.87 | NR1H2 (0.44) | ABHD6DAGLAGPR119NR1H2NR1H3 | |
| SCHEMBL3491920 | 0.85 | ABHD6 (0.38) | ABHD6DAGLAGPR119NR1H2NR1H3 | |
| SCHEMBL3493898 | 0.84 | NR1H2 (0.44) | ABHD6DAGLANR1H2NR1H3DPP4 | |
| SCHEMBL3496189 | 0.84 | NR1H2 (0.46) | ABHD6DAGLANR1H2NR1H3DPP4 | |
| SCHEMBL3494284 | 0.84 | NR1H2 (0.46) | ABHD6DAGLANR1H2NR1H3DPP4 | |
| SCHEMBL3492817 | 0.83 | ABHD6 (0.38) | ABHD6DAGLANR1H2NR1H3KAT7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | ABHD6 2780/4885DAGLA 4388/4885GPR119 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.